Financials Alligator Bioscience AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:29:42 2024-04-26 am EDT			5-day change	1st Jan Change
0.925 ^SEK	+1.09%		-9.14%	+34.25%

Apr. 26	Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	CI
Apr. 05	Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	753.9	567.5	566.9	341.9	453.3	701.2	-	-
Enterprise Value (EV) ¹	574	476.3	298.5	269.1	403.3	403.5	701.2	701.2
P/E ratio	-3.59 x	-3.96 x	-4.02 x	-1.76 x	-1.25 x	-1.74 x	-2.91 x	-7.71 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	140 x	85.1 x	37.5 x	9.21 x	7.32 x	2.64 x	5.17 x	5.36 x
EV / Revenue	106 x	71.4 x	19.7 x	7.25 x	6.52 x	1.52 x	5.17 x	5.36 x
EV / EBITDA	-2.83 x	-3.59 x	-2.29 x	-1.49 x	-1.69 x	58.2 x	-10.6 x	-13.5 x
EV / FCF	-3.17 x	-3.37 x	-2.35 x	-1.56 x	-2.1 x	-2.01 x	-3.58 x	-10.6 x
FCF Yield	-31.6%	-29.7%	-42.6%	-64.3%	-47.5%	-49.8%	-28%	-9.41%
Price to Book	2.92 x	4.92 x	2.01 x	3.88 x	34.5 x	1.97 x	-	-
Nbr of stocks (in thousands)	71,389	71,389	220,585	220,585	657,954	758,039	-	-
Reference price ²	10.56	7.950	2.570	1.550	0.6890	0.9250	0.9250	0.9250
Announcement Date	2/12/20	2/26/21	2/11/22	2/10/23	2/8/24	-	-	-

¹SEK in Million²SEK

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	5.396	6.666	15.13	37.14	61.9	266.1	135.7	130.8
EBITDA ¹	-203	-132.8	-130.4	-181	-238.5	6.93	-66.32	-51.8
EBIT ¹	-214.5	-144.3	-141.6	-192.8	-249	-1.32	-72.82	-58.3
Operating Margin	-3,975.17%	-2,164.69%	-936.14%	-519.16%	-402.22%	-0.5%	-53.68%	-44.57%
Earnings before Tax (EBT) ¹	-210.1	-143.3	-141.7	-193.4	-248.6	-0.98	-72.32	-57.8
Net income ¹	-210.1	-143.3	-141.7	-193.4	-248.6	-0.98	-72.32	-57.8
Net margin	-3,893.85%	-2,149.65%	-936.8%	-520.81%	-401.58%	-0.37%	-53.31%	-44.19%
EPS ²	-2.940	-2.010	-0.6400	-0.8800	-0.5500	-0.5330	-0.3183	-0.1200
Free Cash Flow ¹	-181.1	-141.5	-127.1	-173	-191.7	-201	-196	-66
FCF margin	-3,357.08%	-2,122.02%	-840.13%	-465.99%	-309.76%	-75.53%	-144.46%	-50.46%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-	-
Announcement Date	2/12/20	2/26/21	2/11/22	2/10/23	2/8/24	-	-	-

¹SEK in Million²SEK

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	180	91.3	268	72.8	50	298	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-181	-141	-127	-173	-192	-201	-196	-66
ROE (net income / shareholders' equity)	-57.8%	-76.7%	-71.3%	-104%	-493%	-407%	-311%	-166%
ROA (Net income/ Total Assets)	-51.3%	-61.9%	-58.4%	-76.9%	-173%	-156%	-119%	-50%
Assets ¹	409.6	231.5	242.5	251.4	144	0.6274	60.98	115.6
Book Value Per Share ²	3.620	1.610	1.280	0.4000	0.0200	0.4700	-	-
Cash Flow per Share	-	-	-	-	-	-	-	-
Capex ¹	2.07	0.1	0.05	0.44	2.46	0.03	-	-
Capex / Sales	38.34%	1.53%	0.3%	1.18%	3.97%	0.01%	-	-
Announcement Date	2/12/20	2/26/21	2/11/22	2/10/23	2/8/24	-	-	-

¹SEK in Million²SEK

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

C+

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.925 SEK

Average target price

2.3 SEK

Spread / Average Target

+148.65%

	1st Jan change	Capi.
ALLIGATOR BIOSCIENCE AB	+34.25%	63.95M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B